Thiotepa

Dosage for Thiotepa is highly individualized and is typically calculated based on Body Surface Area (BSA), which uses the patient's height and weight. Healthcare providers follow strict protocols that vary significantly depending on the indication.

• Intravenous Administration (Standard Oncology): The typical dose ranges from 0.3 to 0.4 mg/kg of body weight. These doses are usually administered at intervals of 1 to 4 weeks, depending on how quickly the patient's blood counts recover.
• Intravesical Administration (Bladder Cancer): The standard dose is 30 mg to 60 mg, dissolved in 30-60 mL of sterile water. This solution is instilled into the bladder via a catheter and retained for approximately two hours. This is typically performed once a week for four weeks.
• High-Dose Conditioning (Stem Cell Transplant): Doses are much higher in this setting, often ranging from 150 mg/m² to 300 mg/m² per day, administered over several days as part of a multi-drug regimen.

Thiotepa is used in pediatric patients, primarily in the context of conditioning for hematopoietic stem cell transplantation for both malignant and non-malignant conditions (such as certain genetic blood disorders). Pediatric dosing is also based on BSA or body weight. For example, in some transplant protocols, children may receive 150 mg/m² to 250 mg/m² per dose. Because children's metabolism differs from adults, pediatric oncologists use specialized formulas to ensure safety and efficacy. It is not generally used for standard solid tumor treatment in children outside of clinical trials or specific transplant settings.

Renal Impairment

Thiotepa and its metabolites are cleared through the kidneys. While there are no universal guidelines for specific GFR (Glomerular Filtration Rate) cutoffs, healthcare providers will closely monitor patients with pre-existing kidney disease. Dose reductions may be necessary if kidney function declines during treatment to prevent the accumulation of toxic metabolites.

Hepatic Impairment

Since the liver is responsible for converting Thiotepa into its active metabolite (TEPA), patients with significant liver dysfunction (elevated bilirubin or AST/ALT levels) may process the drug differently. Clinical judgment is used to adjust doses, and treatment may be delayed if liver enzymes are significantly elevated.

Elderly Patients

Older adults (65+) are often more susceptible to the bone marrow-suppressing effects of Thiotepa. Doctors typically start at the lower end of the dosing range and monitor blood counts more frequently in this population.

Thiotepa is never self-administered. It must be prepared and administered by qualified healthcare professionals (oncology nurses or physicians) in a clinical setting such as a hospital or infusion center.

• IV Infusion: It is usually given as a slow injection or a short infusion into a central line or a peripheral IV.
• Bladder Instillation: Patients are often asked to limit fluid intake for 8-12 hours before the procedure so the drug is not diluted by urine. Once the drug is in the bladder, the patient may be asked to change positions (turn from side to side) every 15 minutes to ensure the medication coats the entire bladder lining.
• Storage: Vials of Thiotepa powder must be stored in a refrigerator (2°C to 8°C or 36°F to 46°F) and protected from light.

Because Thiotepa is administered by healthcare professionals on a strict clinical schedule, missing a dose is rare. If an appointment is missed, contact your oncology clinic immediately. Delaying a dose in a chemotherapy cycle can affect the treatment's success, so rescheduling is a high priority.

An overdose of Thiotepa is a medical emergency. Symptoms of overdose are essentially an extreme version of its side effects, primarily profound bone marrow suppression (leading to severe infection or bleeding) and potentially neurotoxicity (confusion or seizures). There is no specific antidote for Thiotepa. Treatment involves supportive care, which may include:

• Blood and platelet transfusions.
• Growth factors (like G-CSF) to stimulate white blood cell production.
• Intensive monitoring for infections and the use of broad-spectrum antibiotics.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to alter your treatment schedule without medical guidance. Always report any new medications you start to your oncology team.

Most patients receiving Thiotepa will experience some level of side effects, particularly those related to the blood and digestive system.

• Myelosuppression (Bone Marrow Suppression): This is the most common and significant side effect. It includes anemia (low red blood cells), which causes fatigue and shortness of breath; leukopenia/neutropenia (low white blood cells), which increases the risk of serious infection; and thrombocytopenia (low platelets), which increases the risk of bruising and bleeding. Blood counts typically reach their lowest point (nadir) 7 to 14 days after treatment.
• Gastrointestinal Issues: Nausea and vomiting are common but are usually manageable with modern anti-nausea medications. Loss of appetite (anorexia) and abdominal pain may also occur.
• Fever and Chills: Often occurring shortly after infusion, sometimes as a direct reaction to the drug or as an early sign of infection.
• Skin Reactions: Particularly in high-dose transplant settings, Thiotepa is excreted through the skin (sweat). This can cause redness, itching, peeling, or even chemical burns if the skin is not cleaned properly.

• Stomatitis (Mouth Sores): Painful sores or inflammation in the mouth and throat, making it difficult to eat or drink.
• Alopecia (Hair Loss): Thinning or total loss of hair. This is usually reversible after treatment ends.
• Headache and Dizziness: General neurological discomfort during or after the infusion.
• Amenorrhea: Interruption of the menstrual cycle in women, which may or may not return after therapy.

• Neurotoxicity: At very high doses, Thiotepa can cause confusion, extreme sleepiness (somnolence), or even seizures. This is more common in patients with pre-existing kidney or liver issues.
• Hepatotoxicity: Damage to the liver, which may manifest as jaundice (yellowing of the eyes/skin) or abnormal liver function tests.
• Secondary Malignancies: Because Thiotepa damages DNA, it can rarely cause a second, different type of cancer (like acute leukemia) years after the original treatment is completed.

> Warning: Stop taking Thiotepa and call your doctor immediately or seek emergency care if you experience any of the following:

• Signs of Infection: Fever over 100.4°F (38°C), chills, sore throat, or a cough that won't go away. In a patient with low white blood cells, an infection can become life-threatening within hours.
• Unusual Bleeding: Nosebleeds that won't stop, bleeding gums, blood in the urine or stool (black, tarry stools), or tiny red spots on the skin (petechiae).
• Severe Allergic Reaction (Anaphylaxis): Swelling of the face, lips, or tongue; difficulty breathing; or a widespread, itchy rash.
• Cognitive Changes: Sudden confusion, inability to wake up, or seizures.
• Severe Skin Peeling: Especially if accompanied by pain or blistering, which may indicate a severe cutaneous reaction.

• Infertility: Thiotepa can cause permanent infertility in both men and women by damaging the ovaries or interfering with sperm production. Patients of childbearing age should discuss fertility preservation (egg or sperm banking) before starting treatment.
• Cognitive Impairment: Some patients report "chemo brain"—lingering difficulties with memory, focus, and multi-tasking that can persist for months or years.
• Secondary Cancers: As mentioned, the risk of developing myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) is a known long-term risk of alkylating agents like Thiotepa.

Thiotepa carries significant FDA-mandated warnings due to its high toxicity profile:

1. 1Severe Myelosuppression: The drug can cause profound and prolonged bone marrow suppression. Death from septicemia (blood poisoning) or hemorrhage has occurred. Frequent blood counts are mandatory.
2. 2Carcinogenicity: Thiotepa is a known human carcinogen. While it treats cancer, it also carries the risk of inducing new cancers, particularly leukemia, in the future.

Report any unusual symptoms, no matter how minor they seem, to your healthcare provider immediately. Early intervention is key to managing chemotherapy side effects.

Thiotepa is a high-alert medication that must only be administered by clinicians experienced in the use of potent antineoplastic (anti-cancer) agents. It has a narrow therapeutic index, meaning the difference between an effective dose and a toxic dose is small. Patients must be committed to frequent laboratory monitoring and follow-up appointments to ensure safety.

According to the FDA-approved labeling, Thiotepa is associated with two primary boxed warnings:

• Bone Marrow Suppression: Thiotepa is highly toxic to the cells in the bone marrow that produce blood. This can lead to dangerously low levels of white blood cells, red blood cells, and platelets. This effect is dose-related and can be fatal if not monitored and managed. Patients must have their complete blood counts (CBC) checked at least weekly during and after treatment.
• Carcinogenicity: Like many alkylating agents, Thiotepa is known to cause cancer in humans. The risk of developing secondary leukemia is increased in patients treated with this drug, especially when used for long periods or in combination with other DNA-damaging therapies.

• Allergic Reactions: While rare, hypersensitivity reactions can occur. Facilities where Thiotepa is administered must be equipped to treat anaphylaxis (severe allergic reaction).
• Skin Toxicity: In high-dose settings, Thiotepa is excreted in sweat. This can lead to severe skin irritation or "thiotepa-induced dermatitis." Patients are often instructed to bathe or shower 3-4 times daily and change clothing/bedding frequently during the days of treatment to wash the drug off the skin.
• Cognitive and Neurological Risk: Thiotepa crosses into the brain. Patients with a history of seizures or those receiving other drugs that affect the central nervous system must be monitored for confusion, hallucinations, or excessive sedation.
• Infection Risk: Because it lowers the immune system, patients should avoid live vaccines (such as the MMR or flu mist) and stay away from people who are sick. Even a minor cold can become dangerous for a patient on Thiotepa.

To ensure the patient is tolerating Thiotepa, healthcare providers will require the following tests:

• Complete Blood Count (CBC): To monitor for anemia, infection risk, and bleeding risk.
• Liver Function Tests (LFTs): To check for drug-induced liver injury.
• Renal Function Tests (BUN/Creatinine): To ensure the kidneys are effectively clearing the drug's metabolites.
• Uric Acid Levels: Rapid killing of cancer cells can release uric acid into the blood (Tumor Lysis Syndrome), which can damage the kidneys.

Thiotepa may cause dizziness, blurred vision, or extreme tiredness. Patients should not drive or operate heavy machinery until they know how the medication affects them. If high doses are used (as in a transplant setting), the patient will likely be hospitalized and unable to perform these activities.

Alcohol should be avoided during Thiotepa treatment. Alcohol can strain the liver, which is already working hard to process the medication, and can worsen gastrointestinal side effects like nausea or stomach irritation.

Thiotepa is typically given in cycles. If a patient experiences severe toxicity (such as a life-threatening infection or organ damage), the doctor may decide to delay the next dose or discontinue the drug entirely. There is no "withdrawal syndrome" associated with stopping Thiotepa, but the underlying cancer may progress if treatment is stopped prematurely.

> Important: Discuss all your medical conditions, especially any history of liver disease, kidney disease, or bone marrow problems, with your healthcare provider before starting Thiotepa.

• Live Vaccines: Vaccines containing live viruses (e.g., yellow fever, oral polio, MMR) must never be given to a patient receiving Thiotepa. Because the drug suppresses the immune system, the vaccine virus could replicate uncontrollably, causing a severe infection.
• Rotavirus Vaccine: Specifically contraindicated in infants who might be receiving Thiotepa for rare conditions, due to the risk of vaccine-derived infection.

• Succinylcholine: Thiotepa inhibits the enzyme pseudocholinesterase, which is responsible for breaking down succinylcholine (a muscle relaxant used during surgery). If a patient needs surgery, they must tell the anesthesiologist they have received Thiotepa, as it can cause prolonged, life-threatening muscle paralysis and inability to breathe (apnea).
• Other Bone Marrow Suppressants: Taking Thiotepa with other chemotherapy drugs or medications like clozapine or linezolid can lead to additive, dangerously low blood counts.
• CYP2B6 Inhibitors: Drugs that inhibit the CYP2B6 enzyme (like paroxetine or clopidogrel) can prevent Thiotepa from being converted into its active metabolite, TEPA, potentially making the treatment less effective.
• CYP3A4 Inducers: Medications like phenytoin, carbamazepine, or rifampin can speed up the metabolism of Thiotepa, which may increase the risk of toxicity or reduce efficacy.

• Anticoagulants (Blood Thinners): Since Thiotepa lowers platelets (which help blood clot), taking it with warfarin, heparin, or aspirin increases the risk of severe internal bleeding.
• NSAIDs: Common painkillers like ibuprofen or naproxen can increase the risk of stomach bleeding and may slightly strain the kidneys, complicating Thiotepa's elimination.

• Grapefruit and Grapefruit Juice: Grapefruit can interfere with the CYP3A4 enzyme system. While Thiotepa is primarily processed by CYP2B6, the involvement of CYP3A4 means grapefruit could potentially alter drug levels. It is best avoided.
• High-Fat Meals: For the rare instances where systemic absorption from intravesical use is a concern, dietary consistency is recommended, though food does not directly affect IV administration.

• St. John’s Wort: This herbal supplement is a potent inducer of liver enzymes and can significantly reduce the levels of Thiotepa in the blood, potentially leading to treatment failure.
• Echinacea: Some studies suggest echinacea may interfere with immunosuppressive therapy; its use should be discussed with an oncologist.
• Antioxidants: High-dose Vitamin C, Vitamin E, or CoQ10 supplements may theoretically interfere with the oxidative damage Thiotepa uses to kill cancer cells. Most oncologists recommend avoiding high-dose antioxidants during active chemotherapy.

Thiotepa can cause false elevations in certain laboratory tests, particularly those related to liver function or uric acid. Always inform the laboratory staff and all treating physicians that you are undergoing chemotherapy with Thiotepa.

For each major interaction, the mechanism usually involves competition for liver enzymes or additive damage to the bone marrow. The clinical consequence is almost always either an increased risk of life-threatening toxicity or a reduction in the drug's ability to fight cancer. Management strategies usually involve selecting alternative medications or performing more frequent blood tests.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.

There are several situations where Thiotepa must NEVER be used because the risks far outweigh any potential benefits:

• Severe Hypersensitivity: Patients who have had a documented life-threatening allergic reaction (anaphylaxis) to Thiotepa or any of its components in the past must not receive it again.
• Severe Bone Marrow Suppression: If a patient already has dangerously low white blood cell counts (neutrophils < 1,500/mm³) or platelet counts (< 100,000/mm³) from previous treatments or disease, Thiotepa is contraindicated until the marrow recovers. Administering it in this state could lead to fatal infection or hemorrhage.
• Pregnancy (Absolute in most contexts): Thiotepa is known to cause severe fetal harm. It should not be started in a pregnant woman unless the life-saving benefit to the mother is deemed to outweigh the near-certain risk to the fetus.
• Live Vaccine Administration: As noted in the interactions section, live vaccines are absolutely contraindicated during and immediately after therapy.

In these cases, a healthcare provider will perform a careful risk-benefit analysis:

• Active Infection: If a patient has an active, uncontrolled bacterial, viral, or fungal infection, Thiotepa should usually be delayed. The drug's ability to lower white blood cells will make it impossible for the body to fight the existing infection.
• Renal or Hepatic Impairment: Patients with significant liver or kidney disease require extreme caution. While not an absolute "never," the risk of drug accumulation and severe neurotoxicity is much higher.
• Recent Radiation Therapy: If a patient has recently received radiation to large areas of bone-bearing marrow (like the pelvis or spine), their marrow reserve may be low, making Thiotepa much more toxic.

Patients who have had allergic reactions to other alkylating agents (such as cyclophosphamide, busulfan, or ifosfamide) may be at a slightly higher risk for a reaction to Thiotepa, although they are chemically distinct. There is also a theoretical risk of cross-sensitivity for patients allergic to other ethylenimine derivatives.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to chemotherapy, before prescribing Thiotepa. Be honest about all past medical issues to ensure your safety.

Thiotepa is classified by the FDA as a Pregnancy Category D (with some modern labeling moving toward the newer PLLR standards indicating clear risk). This means there is positive evidence of human fetal risk based on adverse reaction data.

• Teratogenicity: In animal studies, Thiotepa caused structural abnormalities, growth retardation, and fetal death.
• Advice: Women of childbearing potential must use highly effective contraception during treatment and for at least 6 months after the final dose. Men with female partners of childbearing potential should use effective contraception during and for at least 1 year after treatment, as Thiotepa can damage sperm DNA.

It is unknown if Thiotepa or its metabolites pass into human breast milk. However, because of the potential for serious adverse reactions (including cancer and immune suppression) in a nursing infant, breastfeeding is strictly prohibited during treatment and for at least one week after the last dose. Most clinicians recommend not breastfeeding at all if a mother is undergoing a multi-cycle chemotherapy regimen.

Thiotepa is used in children, primarily for high-dose conditioning before stem cell transplants for conditions like neuroblastoma or certain brain tumors.

• Safety: The side effect profile in children is similar to adults, but there is a higher risk of long-term effects on growth, development, and future fertility.
• Dosing: Pediatric dosing is complex and must be handled by a board-certified pediatric oncologist. It is NOT approved for general use in children for common pediatric cancers outside of these specific high-dose settings.

Clinical studies of Thiotepa did not include enough subjects aged 65 and over to determine if they respond differently than younger subjects. However, elderly patients are more likely to have:

• Reduced Renal Function: Leading to slower clearance of the drug.
• Lower Marrow Reserve: Increasing the risk of severe anemia and infection.
• Polypharmacy: A higher likelihood of drug interactions due to other medications for blood pressure, heart disease, or diabetes.

Since metabolites are excreted renally, patients with a GFR below 60 mL/min should be monitored with extreme care. There is no standard dose-reduction formula, but clinicians may reduce the dose by 25-50% in cases of severe renal failure or choose an alternative agent.

Because the liver activates Thiotepa into TEPA, liver disease can lead to unpredictable drug levels. Patients with a bilirubin > 1.5x the upper limit of normal should be treated with caution. If liver function declines during treatment, Thiotepa may need to be held until the liver recovers.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you are planning a pregnancy or have underlying organ dysfunction.

Thiotepa is a polyfunctional alkylating agent. Its primary molecular mechanism involves the release of ethylenimine radicals. these radicals are highly reactive and form covalent bonds with the DNA of the cell. The most common site of alkylation is the N7 position of guanine.

Once the DNA is alkylated, several things happen:

1. 1Cross-linking: The drug forms bridges between the two strands of DNA, preventing them from separating for replication.
2. 2DNA Fragmentation: The cell's repair enzymes attempt to fix the alkylated bases, often resulting in DNA strand breaks.
3. 3Miscoding: The altered DNA bases cause errors when the cell tries to read the genetic code.

These actions collectively lead to the inhibition of DNA, RNA, and protein synthesis. Because cancer cells lack the robust repair mechanisms of healthy cells, they are unable to fix this damage and undergo apoptosis (cell death).

The anti-tumor effect of Thiotepa is dose-dependent—higher doses result in more DNA cross-linking and greater cell kill, but also higher toxicity. The onset of action is rapid at the molecular level, but the clinical effect (tumor shrinkage or bone marrow suppression) takes days or weeks to manifest. There is no evidence of tolerance development; however, cancer cells can develop resistance by increasing their production of glutathione, which neutralizes the drug before it can reach the DNA.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV); 10-100% (Intravesical) |

| Protein Binding | 10% to 40% |

| Half-life | 2.3 hours (Parent); 3-24 hours (TEPA metabolite) |

| Tmax | Immediate (IV); 1-2 hours (Intravesical) |

| Metabolism | Hepatic via CYP2B6 and CYP3A4 |

| Excretion | Renal (<2% unchanged); remainder as metabolites |

• Molecular Formula: C6H12N3PS
• Molecular Weight: 189.22 g/mol
• Solubility: Highly soluble in water, ethanol, and ether.
• Structure: It consists of a phosphorus atom double-bonded to sulfur and single-bonded to three ethylenimine rings. This compact, lipophilic structure allows it to penetrate cell membranes and the blood-brain barrier easily.

Thiotepa is classified as an Alkylating Drug within the sub-class of Ethylenimines. It is related to other alkylating agents like Cyclophosphamide (a nitrogen mustard) and Busulfan (an alkyl sulfonate), though it has a unique chemical structure that allows for its specific use in bladder instillation and CNS penetration.